Mild cognitive impairment in Parkinson's disease: a distinct clinical entity?
Ming-Ching Wen1,2, Ling Ling Chan3, Louis C S Tan2,4
1Department of Research, National Neuroscience Institute, Singapore, Singapore.
Background:
Mild cognitive impairment in Parkinson's disease (PD-MCI) is a common clinical condition. Understanding its pathology and clinical features is important for early intervention before the onset of dementia. In the past, variable definitions and differences in neuropsychological batteries generated divergent results of the affected cognitive patterns.
Main Body:
The introduction of PD-MCI criteria by the Movement Disorders Society (MDS) Task Force provides a more uniform system for defining and measuring PD-MCI and may improve the validity of future research. PD-MCI is likely to be heterogeneous since it can coexist with Alzheimer's disease and/ or Lewy body pathologies in PD. Pathogeneses of neuropsychiatric disturbances, such as depression, anxiety and apathy, are associated with PD with or without MCI. In addition, cognitive reserve formed by patients' unique life experiences may influence the outward cognitive performance despite the presence of the aforementioned pathogeneses and hence alter the diagnosis of MCI.
Conclusion:
The overlap of cognitive impairment across different neurodegenerative diseases suggests that PD-MCI is likely to result from a mixture of complex pathophysiologies, rather than being a distinct pathologic entity. Differentiating MCI from other organic symptoms in PD would facilitate novel therapeutic strategies.
Insights
Parkinson's disease mild cognitive impairment (PD-MCI) is complex. New criteria aid research, but PD-MCI likely stems from mixed pathologies, not a single cause, requiring tailored treatments.
Area of Science:
- Neuroscience
- Neurology
- Cognitive Science
Background:
- Mild cognitive impairment in Parkinson's disease (PD-MCI) is prevalent.
- Understanding PD-MCI is crucial for early intervention to prevent dementia.
- Previous research faced challenges due to variable definitions and assessment tools.
Purpose of the Study:
- To introduce and utilize the Movement Disorders Society (MDS) Task Force criteria for a standardized approach to PD-MCI.
- To explore the heterogeneity and complex underlying pathologies of PD-MCI.
- To investigate the influence of neuropsychiatric disturbances and cognitive reserve on PD-MCI diagnosis.
Main Methods:
- Application of the Movement Disorders Society (MDS) Task Force criteria for defining and measuring PD-MCI.
- Analysis of potential coexisting pathologies, including Alzheimer's disease and Lewy body pathologies.
- Consideration of neuropsychiatric factors (depression, anxiety, apathy) and cognitive reserve.
Main Results:
- The MDS criteria offer a more uniform system for PD-MCI research.
- PD-MCI is likely a heterogeneous condition.
- Neuropsychiatric disturbances and cognitive reserve can influence cognitive performance and diagnosis.
Conclusions:
- PD-MCI may arise from a combination of complex pathophysiologies rather than a distinct entity.
- The overlap in cognitive impairment across neurodegenerative diseases supports a multifactorial view of PD-MCI.
- Differentiating MCI in PD is essential for developing effective therapeutic strategies.
Related Concept Videos
01:15Parkinson's Disease: Overview
01:24Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
01:26Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
01:30Dementia
The progression of dementia is generally gradual....
01:37Neural Regulation
01:29Intellectual Disability